Literature DB >> 20040515

KSHV downregulation of galectin-3 in Kaposi's sarcoma.

Donald J Alcendor1, Susan M Knobel, Prashant Desai, Wen Q Zhu, Hollie E Vigil, Gary S Hayward.   

Abstract

Galectins are a family of proteins that share an affinity for beta-galactoside containing glycoconjugates. In prostate, ovarian and breast cancer, downregulation of galectin-3 is associated with malignancy and tumor progression. Kaposi's sarcoma (KS) is characterized as an angioproliferative tumor of vascular endothelial cells and produces rare B cell lymphoproliferative diseases in the form of primary effusion lymphomas and some forms of multicentric Castleman's disease. Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of KS. We found reduced levels of galectin-3 expression in a significant fraction of latency-associated nuclear antigen (LANA)-positive spindle cell regions in human archival KS tissue and as measured in KS tissue microarrays. Here we demonstrate that galectin-3 protein expression is downregulated 10-fold in 10-day KSHV-infected dermal microvascular endothelial cells (DMVEC) accompanied by downregulation of message. There is loss of galectin-3 staining in KSHV-infected DMVEC by dual labeled immunohistochemistry in LANA-positive spindle cells. We observed a consistent downregulation of galectin-3 by time-course transcriptional analysis. Of the galectins assayed, only galectin-1 was also downregulated in KSHV-infected DMVEC. We examined 86 KS tumors; 19 were LANA positive (22%) and 67 LANA negative (78%). All 86 tumors were found to be galectin-3 positive; 11 of 19 showed reduced expression of galectin-3 in LANA-positive spindle cell regions. Our data suggest that KSHV vFLIP and LANA are the viral genes targeting galectin-3 downregulation. The contribution of host factors to the pathogenesis of KS is essential for early detection and development of innovative therapies for treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20040515      PMCID: PMC2900887          DOI: 10.1093/glycob/cwp204

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  70 in total

1.  Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.

Authors:  S Ishido; C Wang; B S Lee; G B Cohen; J U Jung
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma.

Authors:  D K Hsu; C A Dowling; K C Jeng; J T Chen; R Y Yang; F T Liu
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

4.  Solution structure of the Kaposi's sarcoma-associated herpesvirus K3 N-terminal domain reveals a Novel E2-binding C4HC3-type RING domain.

Authors:  Roger B Dodd; Mark D Allen; Stephanie E Brown; Christopher M Sanderson; Lidia M Duncan; Paul J Lehner; Mark Bycroft; Randy J Read
Journal:  J Biol Chem       Date:  2004-09-30       Impact factor: 5.157

5.  Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses.

Authors:  D K Hsu; R Y Yang; Z Pan; L Yu; D R Salomon; W P Fung-Leung; F T Liu
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

6.  Activation of NF-kappaB by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype.

Authors:  Claudia Grossmann; Simona Podgrabinska; Mihaela Skobe; Don Ganem
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Kaposi sarcoma herpesvirus K5 removes CD31/PECAM from endothelial cells.

Authors:  Mandana Mansouri; Janet Douglas; Patrick P Rose; Kristine Gouveia; Gary Thomas; Robert E Means; Ashlee V Moses; Klaus Früh
Journal:  Blood       Date:  2006-04-06       Impact factor: 22.113

8.  Decreased galectin-3 expression in prostate cancer.

Authors:  R A Pacis; M J Pilat; K J Pienta; K Wojno; A Raz; V Hogan; C R Cooper
Journal:  Prostate       Date:  2000-07-01       Impact factor: 4.104

9.  Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins.

Authors:  P M Chaudhary; A Jasmin; M T Eby; L Hood
Journal:  Oncogene       Date:  1999-10-14       Impact factor: 9.867

Review 10.  Galectin-3: an open-ended story.

Authors:  Jerka Dumic; Sanja Dabelic; Mirna Flögel
Journal:  Biochim Biophys Acta       Date:  2006-01-18
View more
  2 in total

1.  Identifying dysregulated genes induced by Kaposi's sarcoma-associated herpesvirus (KSHV).

Authors:  Donald Alcendor; Susan Knobel
Journal:  J Vis Exp       Date:  2010-09-14       Impact factor: 1.355

2.  Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.

Authors:  Diego O Croci; Mariana Salatino; Natalia Rubinstein; Juan P Cerliani; Lucas E Cavallin; Howard J Leung; Jing Ouyang; Juan M Ilarregui; Marta A Toscano; Carolina I Domaica; María C Croci; Margaret A Shipp; Enrique A Mesri; Adriana Albini; Gabriel A Rabinovich
Journal:  J Exp Med       Date:  2012-10-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.